Profile
AKAN ZTS TAK HLN TEVA NBIX
Company Name Akanda Corp. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Neurocrine Biosciences, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $3.82M $63.86B $42.85B $42.64B $28.05B $15.29B
Employees 0.05K 13.80K 49.28K 24.56K 37.00K 1.80K
CEO Katharyn Field Kristin C. Peck Christophe Weber Brian James McNamara Richard D. Francis Kyle W. Gano
Ratings
AKAN ZTS TAK HLN TEVA NBIX
Quant Rating Score 2 3 3 3 3 4
Quant Rating Sell Neutral Neutral Neutral Neutral Buy
Trading
AKAN ZTS TAK HLN TEVA NBIX
Last Close $1.33 $119.56 $13.64 $9.41 $24.46 $154.8
High 52 $4.77 $178.71 $15.52 $11.41 $24.6 $154.8
Low 52 $0.67 $119.56 $12.89 $8.73 $12.82 $87.59
Price vs. 52 Week High -72.12 % -33.1 % -12.11 % -17.53 % -0.57 % 0 %
Price vs. 52 Week Low 98.51 % 0 % 5.82 % 7.79 % 90.8 % 76.73 %
Total Return
AKAN ZTS TAK HLN TEVA NBIX
1 Month Return -43.4 % -16.26 % -5.64 % 6.69 % 21.87 % 12.99 %
3 Month Return 3.1 % -19.32 % -5.05 % -0.58 % 50.15 % 23.21 %
6 Month Return 15.27 % -23.31 % -9.43 % -12.59 % 38.98 % 27.23 %
9 Month Return -21.76 % -30.26 % 0.81 % -1.47 % 45.16 % 26.89 %
YTD Return -16.88 % -26.62 % 3.02 % -1.36 % 10.98 % 13.41 %
1 Year Return 67.74 % -31.39 % -1.59 % -1.98 % 39.77 % 24.86 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
AKAN ZTS TAK HLN TEVA NBIX
Dividend Yield Percentage (TTM) - 1.34 % 4.72 % 1.57 % - -
Dividend Paid and Capex Coverage Ration (TTM) -1.9 % 1.89 % 2.01 % 2.01 % 2.78 % 14.57 %
Dividend Per Share (TTM) - 1.93 % 198 % 0.06 % - -
Payout Ratio (TTM) - 32.08 % 226.17 % 27.27 % - -
Growth
AKAN ZTS TAK HLN TEVA NBIX
Asset Growth -10.47 % 0.76 % -9.55 % 14.37 %
Gross Profit Growth 86.98 % -0.19 % 5.47 % 25.65 %
Revenue Growth -61.27 % -0.61 % 4.4 % 24.81 %
Revenue 3 Year 40.03 % 19.01 % 1.52 % 95.79 %
Revenue 5 Year - 33.95 % -5.5 % 172.74 %
Revenue 10 Year - 33.95 % -38.45 % -
EBIT Growth 90.11 % 13.52 % -167.63 % 55.17 %
Net Income Growth 87.31 % 37.46 % -193.2 % 36.68 %
Net Income 3 Yeari Growth Per Share 96.51 % 4.91 % -482.97 % 258.91 %
Net Income 5 Yeari Growth Per Share 84.96 % 122.63 % -58.26 % 741.83 %
Net Income 10 Yeari Growth Per Share 84.96 % 122.63 % -140.46 % 518.75 %
Operating Income Growth 56.4 % 10.52 % -169.98 % 127.38 %
Operating Cash Flow Growth (CFG) -165.26 % 9.57 % -8.85 % 52.71 %
Operating 3 Year CFG 95.79 % 71.6 % 52.26 % 118.72 %
Operating 5 Year CFG 57.03 % 196.04 % 123.59 % 269.64 %
Operating 10 Year CFG 57.03 % 196.04 % -81.66 % 1038.19 %
EPS Growth 93.55 % 33.33 % -190 % 32.81 %
EPS Diluted Growth 93.55 % 33.33 % -190 % 33.2 %
Book Value Per Share 156.8 % -1.63 % -30.36 % 12.91 %
Share Holder 3 Year Equity Growth Per Share 113.47 % -37.97 % -49 % 77.59 %
Share Holder 5 Year Equity Growth Per Share - -40.16 % -62.86 % 271.08 %
Share Holder 10 Year Equity Growth Per Share - -40.16 % -82.6 % 821.72 %
Dividend Per Share Growth - 49.01 % - -
Dividend 3 Year Growth Per Share - -49.79 % - -
Dividend 5 Year Growth Per Share - -49.97 % -100 % -
Dividend 10 Year Growth Per Share - -49.97 % -100 % -
Debt Growth -91.18 % 6.83 % -10.29 % 6.23 %
Free Cash Flow Growth -304.67 % 16.27 % -11.05 % 54.09 %
Updated On 31 Dec 2024 31 Dec 2024 31 Dec 2024 31 Dec 2024
Profitability
AKAN ZTS TAK HLN TEVA NBIX
Gross Profit Margin TTM 24.91 % 70.03 % 52.77 % 61.81 % 49.6 % 98.37 %
Return on Assets TTM -51.76 % 18.04 % 0.98 % 4.78 % -0.39 % 10.03 %
Return on Equity TTM -92.6 % 53.21 % 1.95 % 9.4 % -2.58 % 15.82 %
Return on Capital Employed TTM -102.48 % 31.67 % 4.8 % 8.34 % 3.16 % 15.17 %
Net Income Per EBT TTM 125.32 % 78.72 % 72.4 % 76.52 % 222.54 % 68.09 %
EBT Per Ebit TTM 74.58 % 94.26 % 33.29 % 88.09 % -7.94 % 114.25 %
EBIT Per Revenue TTM -523.8 % 37.51 % 12.68 % 20.49 % 5.38 % 20.51 %
Cash Flow To Debt Ratio TTM -1128.18 % 43.13 % 22.35 % 12.02 % 7.93 % 148.65 %
Receivables Turnover TTM 1.02 6.09 6.59 5.14 4.67 3.69
Payables Turnover TTM 0.21 5.54 5.02 1.18 3.35 0.37
Inventory Turnover TTM - 1.15 1.71 3.72 2.4 0.63
Fixed Asset Turnover TTM 35.77 % 244.46 % 229.02 % 589.57 % 321.73 % 473.81 %
Asset Turnover TTM 10.57 % 64.82 % 31.99 % 34.62 % 41.43 % 62.89 %
Operating Cash Flow Per Share TTM -3.82 6.58 643.53 0.11 1.21 6.41
Free Cash Flow Per Share TTM -5.83 4.99 521.29 0.1 0.78 5.97
Cash Per Share TTM 368.39 % 322.4 % 22368.59 % 7.46 % 188.4 % 1121.53 %
Operating Cash Flow Sales Ratio TTM -475.74 % 31.21 % 22.48 % 9.32 % 8.36 % 23.74 %
Free Cash Flow Operating Cash Flow Ratio TTM 152.71 % 75.76 % 81.01 % 90.65 % 64.03 % 93.14 %
Cash Flow Coverage Ratios TTM -1128.18 % 43.13 % 22.35 % 12.02 % 7.93 % 148.65 %
Price To Free Cash Flows Ratio TTM -0.63 28.78 8.1 34.18 31.29 25.77
Price To Operating Cash Flows Ratio TTM -0.44 21.9 6.51 31.51 20.03 24
Price Cash Flow Ratio TTM -0.44 21.9 6.51 31.51 20.03 24
Income Statement (TTM)
AKAN ZTS TAK HLN TEVA NBIX
Revenue $0B $9.26B $4581.55B $11.23B $16.54B $2.36B
Gross Profit $0B $6.4B $3001.33B $6.95B $8.06B $2.32B
Gross Profit Ratio 24.91% 69.1% 65.51% 61.85% 48.74% 98.56%
EBITDA $-0B $3.87B $1210.51B $2.51B $0.78B $0.64B
Net Income $-0B $2.49B $107.93B $1.44B $-1.64B $0.34B
EPS Diluted -3.93 5.47 33.62 0.32 -1.45 3.29
Balance Sheet (MRQ)
AKAN ZTS TAK HLN TEVA NBIX
Long Term Debt $0B $5.39B $4517.23B $8.62B $16.3B $0.46B
Total Liabilities $0B $9.47B $7312.37B $18.09B $33.61B $1.13B
Total Equity $0B $4.77B $6935.98B $16.22B $5.72B $2.59B
Total Investments $0B $0.03B $382.4B $0.08B $0B $1.71B
Total Debt $0B $6.74B $5066.17B $10.1B $18.08B $0.46B
Total Assets $0.01B $14.24B $14248.34B $34.32B $39.33B $3.72B
Cash Flow Statement (TTM)
AKAN ZTS TAK HLN TEVA NBIX
Net Income $-0B $2.5B $107.93B $1.44B $-1.96B $0.34B
Inventory $0B $-0.04B $-34.97B $0.22B $0.17B $-0.02B
Dividends Paid $0B $-0.79B $-302.5B $-0.57B $0B $0B
Operating Cash Flow $-0B $2.95B $1057.18B $2.3B $1.25B $0.6B
Capital Expenditure $-0B $-0.66B $-200.8B $-0.25B $-0.5B $-0.04B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.555
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 5.705
ALVOW Alvotech 0.78
AMPH Amphastar Pharmaceuticals, Inc. 24.04
AMRX Amneal Pharmaceuticals, Inc. 11.37
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 90.49
APUS Apimeds Pharmaceuticals US, Inc 2.2899
AQST Aquestive Therapeutics, Inc. 6.045
ASRT Assertio Holdings, Inc. 0.7609
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 18.7
AYTU Aytu BioPharma, Inc. 2.03
ETFs With Exposure to AKAN
Ticker ETF Name Weight Percentage Price
MJ ETFMG Alternative Harvest ETF 0 29.78
Unlock